We suggest that CHPG and potentially other mGluR5 agonists may directly impact OPCs to influence conditions such as white matter injury in preterm infants [40–42], or juvenile MS [43–45] where white matter deficits are evident. Here, GRM5 is linked to myeloid sarcoma.